BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005;21:733-738. [PMID: 15771759 DOI: 10.1111/j.1365-2036.2005.02405.x] [Cited by in Crossref: 196] [Cited by in F6Publishing: 168] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
2 Babalola O, Strober BE. Management of psoriasis in pregnancy: Treatment of cutaneous disorders of pregnancy. Dermatol Ther 2013;26:285-92. [DOI: 10.1111/dth.12073] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
3 Garrido E, Van Domselaar M, Morales S, López-sanromán A. Enfermedad inflamatoria intestinal y gestación. Gastroenterología y Hepatología 2010;33:517-29. [DOI: 10.1016/j.gastrohep.2009.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Huang VW, Chang HJ, Kroeker KI, Goodman KJ, Hegadoren KM, Dieleman LA, Fedorak RN. Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education. Can J Gastroenterol Hepatol 2016;2016:6193275. [PMID: 27725926 DOI: 10.1155/2016/6193275] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
5 Kwan LY, Mahadevan U. Inflammatory bowel disease and pregnancy: an update. Expert Rev Clin Immunol. 2010;6:643-657. [PMID: 20594137 DOI: 10.1586/eci.10.35] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
6 Mozaffari S, Abdolghaffari A, Nikfar S, Abdollahi M. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: A systematic review with meta-analysis. Hum Exp Toxicol 2015;34:445-59. [DOI: 10.1177/0960327114550882] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
7 Long MD. Infertility in Inflammatory Bowel Diseases: A Cause for Hope? Clin Gastroenterol Hepatol 2015;13:1647-9. [PMID: 25987300 DOI: 10.1016/j.cgh.2015.05.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Skomsvoll JF, Wallenius M, Koksvik HS, Rødevand E, Salvesen KA, Spigset O, Kvien TK. Drug insight: Anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation. Nat Clin Pract Rheumatol. 2007;3:156-164. [PMID: 17334338 DOI: 10.1038/ncprheum0426] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
9 Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum 2009;61:587-92. [PMID: 19404999 DOI: 10.1002/art.24462] [Cited by in Crossref: 59] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
10 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.5] [Reference Citation Analysis]
11 Wozel G, Sticherling M. Systemische Psoriasistherapie – der nächste Schritt: Adalimumab. Hautarzt 2007;58:515-24. [DOI: 10.1007/s00105-007-1338-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Pedersen N, Bortoli A, Duricova D, D Inca R, Panelli MR, Gisbert JP, Zoli G, López-Sanromán A, Castiglione F, Riegler G. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther. 2013;38:501-512. [PMID: 23855425 DOI: 10.1111/apt.12412] [Cited by in Crossref: 102] [Cited by in F6Publishing: 81] [Article Influence: 12.8] [Reference Citation Analysis]
13 Ben-Horin S, Yavzori M, Kopylov U, Picard O, Fudim E, Eliakim R, Chowers Y, Lang A. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2011;5:555-558. [PMID: 22115374 DOI: 10.1016/j.crohns.2011.05.006] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 8.0] [Reference Citation Analysis]
14 Beaulieu DB, Kane S. Inflammatory bowel disease in pregnancy. Gastroenterol Clin North Am. 2011;40:399-413, ix. [PMID: 21601787 DOI: 10.1016/j.gtc.2011.03.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
15 Habal FM, Ravindran NC. Management of inflammatory bowel disease in the pregnant patient. World J Gastroenterol 2008; 14(9): 1326-1332 [PMID: 18322943 DOI: 10.3748/wjg.14.1326] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
16 Lockshin MD. Treating rheumatic diseases in pregnancy: dos and don'ts. Ann Rheum Dis 2006;65 Suppl 3:iii58-60. [PMID: 17038475 DOI: 10.1136/ard.2006.058420] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
17 Correia LM, Bonilha DQ, Ramos JD, Ambrogini O, Miszputen SJ. Inflammatory bowel disease and pregnancy: report of two cases treated with infliximab and a review of the literature: . European Journal of Gastroenterology & Hepatology 2010;22:1260-4. [DOI: 10.1097/meg.0b013e328329543a] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
18 Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's Disease. Journal of Crohn's and Colitis 2010;4:603-5. [DOI: 10.1016/j.crohns.2010.05.001] [Cited by in Crossref: 229] [Cited by in F6Publishing: 192] [Article Influence: 20.8] [Reference Citation Analysis]
19 Sheth N, Greenblatt DT, Acland K, Barker J, Teixeira F. Generalized pustular psoriasis of pregnancy treated with infliximab. Clinical and Experimental Dermatology 2009;34:521-2. [DOI: 10.1111/j.1365-2230.2008.02963.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
20 Hagen-hurley T. Conception, fertility and pregnancy inwomen with inflammatory bowel disease. Gastrointestinal Nursing 2008;6:34-9. [DOI: 10.12968/gasn.2008.6.4.29385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106:214-223; quiz 224. [PMID: 21157441 DOI: 10.1038/ajg.2010.464] [Cited by in Crossref: 146] [Cited by in F6Publishing: 117] [Article Influence: 13.3] [Reference Citation Analysis]
22 Saha S, Wald A. Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease. Expert Opin Drug Saf. 2012;11:947-957. [PMID: 22954378 DOI: 10.1517/14740338.2012.720970] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
23 Chiam NP, Lim LL. Uveitis and gender: the course of uveitis in pregnancy. J Ophthalmol 2014;2014:401915. [PMID: 24683491 DOI: 10.1155/2014/401915] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
24 Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis. 2010;16:881-895. [PMID: 19885906 DOI: 10.1002/ibd.21154] [Cited by in Crossref: 102] [Cited by in F6Publishing: 78] [Article Influence: 9.3] [Reference Citation Analysis]
25 Habal FM, Kapila V. Inflammatory bowel disease and pregnancy: evidence, uncertainty and patient decision-making. Can J Gastroenterol 2009;23:49-53. [PMID: 19172209 DOI: 10.1155/2009/531638] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
26 Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426-1438. [PMID: 23752881 DOI: 10.1038/ajg.2013.171] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 10.5] [Reference Citation Analysis]
27 Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res 2017;15:285-310. [PMID: 28670226 DOI: 10.5217/ir.2017.15.3.285] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
28 Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31281-7. [PMID: 32931960 DOI: 10.1016/j.cgh.2020.09.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
29 Østensen M. Management of early aggressive rheumatoid arthritis during pregnancy and lactation. Expert Opinion on Pharmacotherapy 2009;10:1469-79. [DOI: 10.1517/14656560902980194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
30 Soh MC, Mackillop L. Biologics in pregnancy - for the obstetrician. Obstet Gynecol 2016;18:25-32. [DOI: 10.1111/tog.12250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
31 Al Hammadi A, Al-haddab M, Sasseville D. Dermatologic Treatment during Pregnancy: Practical Overview. J Cutan Med Surg 2006;10:183-92. [DOI: 10.2310/7750.2006.00043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
32 Vermeire S, Carbonnel F, Coulie PG, Geenen V, Hazes JM, Masson PL, De Keyser F, Louis E. Management of inflammatory bowel disease in pregnancy. J Crohns Colitis. 2012;6:811-823. [PMID: 22595185 DOI: 10.1016/j.crohns.2012.04.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
33 Thukral C, Wolf JL. Therapy Insight: drugs for gastrointestinal disorders in pregnant women. Nat Rev Gastroenterol Hepatol 2006;3:256-66. [DOI: 10.1038/ncpgasthep0452] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
34 Robinson AA, Watson WJ, Leslie KK. Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. The Lancet Oncology 2007;8:738-43. [DOI: 10.1016/s1470-2045(07)70242-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
35 Sheibani S, Mahadevan U. Editorial: Are thiopurines and anti-TNFα agents safe to use in pregnant patients with inflammatory bowel disease? Am J Gastroenterol 2013;108:441-3. [PMID: 23459048 DOI: 10.1038/ajg.2012.436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
36 Fasoulakis Z, Antsaklis P, Galanopoulos N, Kontomanolis E. Common Adverse Effects of Anti-TNF Agents on Gestation. Obstet Gynecol Int 2016;2016:8648651. [PMID: 28044081 DOI: 10.1155/2016/8648651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
37 Pentšuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: New insights into developmental toxicity testing of monoclonal antibodies. Birth Defect Res B 2009;86:328-44. [DOI: 10.1002/bdrb.20201] [Cited by in Crossref: 177] [Cited by in F6Publishing: 141] [Article Influence: 14.8] [Reference Citation Analysis]
38 Huang VW, Habal FM. From conception to delivery: Managing the pregnant inflammatory bowel disease patient. World J Gastroenterol 2014; 20(13): 3495-3506 [PMID: 24707132 DOI: 10.3748/wjg.v20.i13.3495] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
39 Horst S, Kane S. The use of biologic agents in pregnancy and breastfeeding. Gastroenterol Clin North Am 2014;43:495-508. [PMID: 25110255 DOI: 10.1016/j.gtc.2014.05.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
40 Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs. 2010;24 Suppl 1:3-14. [PMID: 21175228 DOI: 10.2165/11586290-000000000-00000] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 5.6] [Reference Citation Analysis]
41 Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-melton M, Outman R, Allison JJ, Almazor MS, Bridges SL, Chatham WW, Hochberg M, Maclean C, Mikuls T, Moreland LW, O'dell J, Turkiewicz AM, Furst DE. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. [DOI: 10.1002/art.23721] [Cited by in Crossref: 986] [Cited by in F6Publishing: 785] [Article Influence: 75.8] [Reference Citation Analysis]
42 Winter R, Nørgård BM, Friedman S. Treatment of the Pregnant Patient with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22:733-744. [PMID: 26658216 DOI: 10.1097/MIB.0000000000000625] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
43 Okoro NI, Kane SV. Gender-related issues in the female inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol. 2009;3:145-154. [PMID: 19351285 DOI: 10.1586/egh.09.1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
44 Ng WT, Lee S, McRae A, Francis IC, Wakefield D. Genital ulceration in a febrile patient with poor vision: a presentation of presumed Behçet's disease. Aust N Z J Obstet Gynaecol 2008;48:445-6. [PMID: 18837855 DOI: 10.1111/j.1479-828X.2008.00895.x] [Reference Citation Analysis]
45 Kane S. Gender Issues in Inflammatory Bowel Disease. Womens Health (Lond Engl) 2005;1:401-7. [DOI: 10.2217/17455057.1.3.401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
46 Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S. Anti-TNF therapy and pregnancy outcomes in women with inflammatory arthritis. Expert Rev Clin Immunol. 2009;5:27-34. [PMID: 20476897 DOI: 10.1586/1744666x.5.1.27] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
47 Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Inflamm Bowel Dis. 2008;14:1736-1750. [PMID: 18626967 DOI: 10.1002/ibd.20532] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 5.6] [Reference Citation Analysis]
48 Stephansson O, Larsson H, Pedersen L, Kieler H, Granath F, Ludvigsson JF, Falconer H, Ekbom A, Sørensen HT, Nørgaard M. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis. 2011;17:795-801. [PMID: 20564537 DOI: 10.1002/ibd.21369] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 7.6] [Reference Citation Analysis]
49 Caviglia R, Boškoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opinion on Drug Safety 2008;7:617-32. [DOI: 10.1517/14740338.7.5.617] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
50 Louchet M, Sibiude J, Peytavin G, Picone O, Tréluyer JM, Mandelbrot L. Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. Am J Obstet Gynecol MFM 2020;2:100159. [PMID: 32838264 DOI: 10.1016/j.ajogmf.2020.100159] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
51 Chambers CD, Tutuncu ZN, Johnson D, Jones KL. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther. 2006;8:215. [PMID: 16774693 DOI: 10.1186/ar1977] [Cited by in Crossref: 58] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
52 Martin PL, Oneda S, Treacy G. Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am J Reprod Immunol. 2007;58:138-149. [PMID: 17631007 DOI: 10.1111/j.1600-0897.2007.00499.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 6.1] [Reference Citation Analysis]
53 Chaparro M, Gisbert JP. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease? Expert Opinion on Drug Safety 2014;13:1749-62. [DOI: 10.1517/14740338.2014.959489] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
54 Cornish J, Tan E, Teare J, Teoh TG, Rai R, Clark SK, Tekkis PP. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56:830-837. [PMID: 17185356 DOI: 10.1136/gut.2006.108324] [Cited by in Crossref: 285] [Cited by in F6Publishing: 245] [Article Influence: 19.0] [Reference Citation Analysis]
55 Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol 2008; 14(19): 3085-3087 [PMID: 18494064 DOI: 10.3748/wjg.14.3085] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 58] [Article Influence: 5.5] [Reference Citation Analysis]
56 Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:823-826. [PMID: 21362710 DOI: 10.1136/ard.2010.140822] [Cited by in Crossref: 125] [Cited by in F6Publishing: 106] [Article Influence: 12.5] [Reference Citation Analysis]
57 Plavšić I, Stimac T, Hauser G. Crohn's disease in women. Int J Womens Health 2013;5:681-8. [PMID: 24204175 DOI: 10.2147/IJWH.S38083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
58 Jang YW, Park YS, Kim SH, Jo YJ, Jo YK, Ahn SB, Seo YS, Hong YO. A Case of Crohn's Disease Having Normal Delivery after Infliximab Treatment during Early Pregnancy. Korean J Gastroenterol 2013;61:37. [DOI: 10.4166/kjg.2013.61.1.37] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
59 Kammerlander H, Nielsen J, Kjeldsen J, Knudsen T, Friedman S, Nørgård B. The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1011-8. [PMID: 28346274 DOI: 10.1097/MIB.0000000000001102] [Cited by in Crossref: 57] [Cited by in F6Publishing: 11] [Article Influence: 19.0] [Reference Citation Analysis]
60 Androulakis I, Zavos C, Christopoulos P, Mastorakos G, Gazouli M. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease. World J Gastroenterol 2015; 21(47): 13205-13211 [PMID: 26715803 DOI: 10.3748/wjg.v21.i47.13205] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
61 Aratari A, Margagnoni G, Koch M, Papi C. Intentional infliximab use during pregnancy for severe steroid-refractory ulcerative colitis. J Crohns Colitis. 2011;5:262. [PMID: 21575893 DOI: 10.1016/j.crohns.2011.02.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
62 Kammerlander H, Nielsen J, Knudsen T, Kjeldsen J, Friedman S, Nørgård BM. Anti–TNF-α Use During the Third Trimester of Pregnancy in Women with Moderate–severe Inflammatory Bowel Disease and the Risk of Preterm Birth and Low Birth Weight: . Inflammatory Bowel Diseases 2017;23:1916-23. [DOI: 10.1097/mib.0000000000001234] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
63 Ye BD, Yang S, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim Y, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Guidelines for the Management of Crohn's Disease. Intest Res 2012;10:26. [DOI: 10.5217/ir.2012.10.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
64 Clowse ME, Wolf DC, Förger F, Cush JJ, Golembesky A, Shaughnessy L, De Cuyper D, Mahadevan U. Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol. J Rheumatol 2015;42:2270-8. [DOI: 10.3899/jrheum.140189] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 8.5] [Reference Citation Analysis]
65 Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
66 Moffatt DC, Bernstein CN. Drug therapy for inflammatory bowel disease in pregnancy and the puerperium. Best Practice & Research Clinical Gastroenterology 2007;21:835-47. [DOI: 10.1016/j.bpg.2007.05.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
67 Dubertret L, Chimenti S, Christophers E, Daudén E, de Rie M, Griffiths CEM, Kragballe K, Ståhle M, Stingl G. Alice, Eloi, Magali and Robert: the lives of four patients with psoriasis and the therapeutic approaches of eight European experts. British Journal of Dermatology 2009;161:1-30. [DOI: 10.1111/j.1365-2133.2009.09173.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
68 Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;40:338-353. [PMID: 24957164 DOI: 10.1111/apt.12838] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 9.4] [Reference Citation Analysis]
69 Raja H, Matteson EL, Michet CJ, Smith JR, Pulido JS. Safety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding. Transl Vis Sci Technol 2012;1:6. [PMID: 24049706 DOI: 10.1167/tvst.1.2.6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
70 Pucino F, Harbus PT, Goldbach-mansky R. Use of biologics in rheumatoid arthritis: Where are we going? American Journal of Health-System Pharmacy 2006;63:S19-41. [DOI: 10.2146/ajhp060365] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
71 Angelucci E, Cocco A, Viscido A, Caprilli R. Safe use of infliximab for the treatment of fistulizing Crohn’s disease during pregnancy within 3 months of conception. Inflamm Bowel Dis. 2008;14:435-436. [PMID: 18050300 DOI: 10.1002/ibd.20319] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
72 Salari P, Nikfar S, Abdollahi M. Current opinion on treatment of inflammatory bowel disease in pregnant women. Arch Med Sci. 2012;8:983-986. [PMID: 23319970 DOI: 10.5114/aoms.2012.32403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
73 Bortoli A, Pedersen N, Duricova D, D'Inca R, Gionchetti P, Panelli MR, Ardizzone S, Sanroman AL, Gisbert JP, Arena I, Riegler G, Marrollo M, Valpiani D, Corbellini A, Segato S, Castiglione F, Munkholm P; European Crohn-Colitis Organisation (ECCO) Study Group of Epidemiologic Committee (EpiCom). Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther. 2011;34:724-734. [PMID: 21815900 DOI: 10.1111/j.1365-2036.2011.04794.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 95] [Article Influence: 10.5] [Reference Citation Analysis]
74 Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. Journal of the American Academy of Dermatology 2008;59:295-315. [DOI: 10.1016/j.jaad.2008.03.018] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
75 Habal FM, Huang VW. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther. 2012;35:501-515. [PMID: 22221203 DOI: 10.1111/j.1365-2036.2011.04967.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
76 Ali YM, Kuriya B, Orozco C, Cush JJ, Keystone EC. Can tumor necrosis factor inhibitors be safely used in pregnancy? J Rheumatol 2010;37:9-17. [PMID: 20008917 DOI: 10.3899/jrheum.090563] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
77 Leung WK, Ng SC, Chow DK, Lao WC, Leung VK, Li MK, Hui YT, Ng SS, Hui AJ, Lai ST. Use of biologics for inflammatory bowel disease in Hong Kong: consensus statement. Hong Kong Med J. 2013;19:61-68. [PMID: 23378357 DOI: 10.1007/s00535-012-0673-1] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 9.3] [Reference Citation Analysis]
78 Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: A systematic literature review. World J Gastroenterol 2013; 19(17): 2591-2602 [PMID: 23674866 DOI: 10.3748/wjg.v19.i17.2591] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 56] [Article Influence: 9.0] [Reference Citation Analysis]
79 Mahadevan U. Pregnancy and Inflammatory Bowel Disease. Medical Clinics of North America 2010;94:53-73. [DOI: 10.1016/j.mcna.2009.08.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
80 Orlando A, Mocciaro F, Civitavecchia G, Scimeca D, Cottone M. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. Digestive and Liver Disease 2008;40:S236-46. [DOI: 10.1016/s1590-8658(08)60532-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
81 Kroser J, Srinivasan R. Drug Therapy of Inflammatory Bowel Disease in Fertile Women. Am J Gastroenterology 2006;101:S633-9. [DOI: 10.1111/j.1572-0241.2006.00961.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
82 Dessinioti C, Stefanaki I, Stratigos AJ, Kostaki M, Katsambas A, Antoniou C. Pregnancy during adalimumab use for psoriasis. J Eur Acad Dermatol Venereol. 2011;25:738-739. [PMID: 20569288 DOI: 10.1111/j.1468-3083.2010.03756.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
83 Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim YH, Lee H. [Guidelines for the management of Crohn’s disease]. Korean J Gastroenterol. 2012;59:141-179. [PMID: 22387837 DOI: 10.4166/kjg.2012.59.2.141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
84 Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009; 15(17): 2067-2073 [PMID: 19418577 DOI: 10.3748/wjg.15.2067] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 67] [Article Influence: 5.8] [Reference Citation Analysis]
85 Garip Y. Use of biologic agents for rheumatic diseases in pregnancy. World J Rheumatol 2015; 5(2): 50-58 [DOI: 10.5499/wjr.v5.i2.50] [Reference Citation Analysis]
86 Schulze H, Esters P, Dignass A. Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation. Aliment Pharmacol Ther 2014;40:991-1008. [PMID: 25200000 DOI: 10.1111/apt.12949] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
87 Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations. J Crohns Colitis. 2010;4:63-101. [PMID: 21122490 DOI: 10.1016/j.crohns.2009.09.009] [Cited by in Crossref: 540] [Cited by in F6Publishing: 466] [Article Influence: 45.0] [Reference Citation Analysis]
88 管丽芳, 胡博文, 孙琳, 廉方, 刘同亭. 妊娠期炎症性肠病的治疗策略与动态管理. 世界华人消化杂志 2016; 24(28): 3978-3984 [DOI: 10.11569/wcjd.v24.i28.3978] [Reference Citation Analysis]
89 Barenbrug L, Groen MT, Hoentjen F, van Drongelen J, Reek JMPAVD, Joosten I, de Jong EMGJ, van der Molen RG. Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-α during pregnancy: A systemic review and meta-analysis. J Autoimmun 2021;122:102676. [PMID: 34126302 DOI: 10.1016/j.jaut.2021.102676] [Reference Citation Analysis]
90 Mahadevan U. Fertility and pregnancy in the patient with inflammatory bowel disease. Gut. 2006;55:1198-1206. [PMID: 16849349 DOI: 10.1136/gut.2005.078097] [Cited by in Crossref: 94] [Cited by in F6Publishing: 73] [Article Influence: 6.3] [Reference Citation Analysis]
91 Nielsen OH, Loftus EV, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med. 2013;11:174. [PMID: 23902720 DOI: 10.1186/1741-7015-11-174] [Cited by in Crossref: 80] [Cited by in F6Publishing: 71] [Article Influence: 10.0] [Reference Citation Analysis]
92 de Lima A, Zelinkova Z, van der Ent C, Steegers EA, van der Woude CJ. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut. 2016;65:1261-1268. [PMID: 25966992 DOI: 10.1136/gutjnl-2015-309321] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 11.8] [Reference Citation Analysis]
93 Lioté F. Médicaments rhumatologiques autorisés pendant la grossesse. Revue du Rhumatisme 2005;72:755-60. [DOI: 10.1016/j.rhum.2005.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
94 O’Donnell S, O’Morain C. Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment Pharmacol Ther. 2008;27:885-894. [PMID: 18284649 DOI: 10.1111/j.1365-2036.2008.03648.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
95 Kane S. IBD: Activity of IBD during pregnancy. Nat Rev Gastroenterol Hepatol. 2013;10:571-572. [PMID: 23938453 DOI: 10.1038/nrgastro.2013.152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
96 Mottet C, Juillerat P, Pittet V, Gonvers J, Froehlich F, Vader J, Michetti P, Felley C. Pregnancy and Breastfeeding in Patients with Crohn’s Disease. Digestion 2008;76:149-60. [DOI: 10.1159/000111030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
97 Tandon P, Govardhanam V, Leung K, Maxwell C, Huang V. Systematic review with meta-analysis: risk of adverse pregnancy-related outcomes in inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:320-33. [DOI: 10.1111/apt.15587] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
98 Østensen M, Förger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol. 2009;5:382-390. [PMID: 19506586 DOI: 10.1038/nrrheum.2009.103] [Cited by in Crossref: 91] [Cited by in F6Publishing: 73] [Article Influence: 7.6] [Reference Citation Analysis]
99 Reddy JG, Loftus EV. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am. 2006;35:837-855. [PMID: 17129816 DOI: 10.1016/j.gtc.2006.09.008] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 4.8] [Reference Citation Analysis]
100 Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161:987-1019. [PMID: 19857207 DOI: 10.1111/j.1365-2133.2009.09505.x] [Cited by in Crossref: 308] [Cited by in F6Publishing: 260] [Article Influence: 28.0] [Reference Citation Analysis]
101 Allez M. [Practical use of anti-TNF monoclonal antibodies in inflammatory bowel diseases]. Gastroenterol Clin Biol 2008;32:467-77. [PMID: 18448294 DOI: 10.1016/j.gcb.2008.03.002] [Reference Citation Analysis]
102 Cassina M, Fabris L, Okolicsanyi L, Gervasi MT, Memmo A, Tiboni GM, Di Gianantonio E, Clementi M. Therapy of inflammatory bowel diseases in pregnancy and lactation. Expert Opinion on Drug Safety 2009;8:695-707. [DOI: 10.1517/14740330903357463] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
103 Martin PL, Cornacoff JB, Treacy G, Eirikas E, Marini J, White KL, Peachee V, Hoberman A. Effects of Administration of a Monoclonal Antibody against Mouse Tumor Necrosis Factor Alpha during Pregnancy and Lactation on the Pre- and Postnatal Development of the Mouse Immune System. Int J Toxicol 2008;27:341-7. [DOI: 10.1080/10915810802368196] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
104 Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn’s disease before and after delivery. J Clin Gastroenterol. 2009;43:613-616. [PMID: 19142167 DOI: 10.1097/mcg.0b013e31817f9367] [Cited by in Crossref: 104] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
105 Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, Spitz B, Hoffman I, Van Steen K, Vermeire S. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011;17:1846-1854. [PMID: 21830263 DOI: 10.1002/ibd.21583] [Cited by in Crossref: 127] [Cited by in F6Publishing: 117] [Article Influence: 12.7] [Reference Citation Analysis]
106 Berthelot JM, De Bandt M, Goupille P, Solau-Gervais E, Lioté F, Goeb V, Azaïs I, Martin A, Pallot-Prades B, Maugars Y. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine. 2009;76:28-34. [PMID: 19059799 DOI: 10.1016/j.jbspin.2008.04.016] [Cited by in Crossref: 83] [Cited by in F6Publishing: 70] [Article Influence: 6.4] [Reference Citation Analysis]
107 Abrouk M, Beroukhim K, Nakamura M, Zhu TH, Farahnik B, Singh R, Brodsky M, Lee K, Koo J, Bhutani T. Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule. Int J Womens Dermatol 2016;2:62-4. [PMID: 28492009 DOI: 10.1016/j.ijwd.2016.02.001] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
108 Stephansson O, Larsson H, Pedersen L, Kieler H, Granath F, Ludvigsson JF, Falconer H, Ekbom A, Sørensen HT, Nørgaard M. Crohn's disease is a risk factor for preterm birth. Clin Gastroenterol Hepatol. 2010;8:509-515. [PMID: 20202483 DOI: 10.1016/j.cgh.2010.02.014] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 7.1] [Reference Citation Analysis]
109 Mountifield R, Andrews JM, Bampton P. It IS worth the effort: Patient knowledge of reproductive aspects of inflammatory bowel disease improves dramatically after a single group education session. J Crohns Colitis. 2014;8:796-801. [PMID: 24467964 DOI: 10.1016/j.crohns.2013.12.019] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
110 Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf 2014. [DOI: 10.1517/14740338.2015.973399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
111 Leung KK, Tandon P, Govardhanam V, Maxwell C, Huang V. The Risk of Adverse Neonatal Outcomes With Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2021;27:550-62. [PMID: 32469057 DOI: 10.1093/ibd/izaa122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
112 Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006;4:1255-1258. [PMID: 17045211 DOI: 10.1016/j.cgh.2006.07.018] [Cited by in Crossref: 198] [Cited by in F6Publishing: 164] [Article Influence: 14.1] [Reference Citation Analysis]
113 Heetun ZS, Byrnes C, Neary P, O’morain C. Review article: reproduction in the patient with inflammatory bowel disease: REVIEW: REPRODUCTION AND INFLAMMATORY BOWEL DISEASE. Alimentary Pharmacology & Therapeutics 2007;26:513-33. [DOI: 10.1111/j.1365-2036.2007.03397.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 5.2] [Reference Citation Analysis]
114 Elliott AB, Chakravarty EF. Immunosuppressive Medications during Pregnancy and Lactation in Women with Autoimmune Diseases. Womens Health (Lond Engl) 2010;6:431-42. [DOI: 10.2217/whe.10.24] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
115 Mahadevan U. Pregnancy and inflammatory bowel disease. Gastroenterol Clin North Am. 2009;38:629-649. [PMID: 19913206 DOI: 10.1016/j.gtc.2009.07.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
116 Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn’s disease. Inflamm Bowel Dis. 2011;17:2366-2391. [PMID: 21337669 DOI: 10.1002/ibd.21655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
117 Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006;131:283-311. [PMID: 16831611 DOI: 10.1053/j.gastro.2006.04.049] [Cited by in Crossref: 93] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
118 Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, Doria A, Rai R, Meroni P, Cetin I. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8:209. [PMID: 16712713 DOI: 10.1186/ar1957] [Cited by in Crossref: 350] [Cited by in F6Publishing: 275] [Article Influence: 23.3] [Reference Citation Analysis]
119 Chaudrey KH, Kane SV. Safety of Immunomodulators and Anti-TNF Therapy in Pregnancy. Curr Treat Options Gastro 2015;13:77-89. [DOI: 10.1007/s11938-014-0037-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
120 Natsumi I, Matsukawa Y, Miyagawa K, Kodaira H, Tanaka T, Horikoshi A, Takeuchi J, Takei M, Maejima M, Akimoto J. Successful childbearing in two women with rheumatoid arthritis and a history of miscarriage after etanercept treatment. Rheumatol Int 2013;33:2433-5. [DOI: 10.1007/s00296-012-2433-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
121 Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (Humira) for Crohn’s disease in pregnancy. Inflamm Bowel Dis. 2006;12:827-828. [PMID: 16917239 DOI: 10.1097/00054725-200608000-00020] [Cited by in Crossref: 92] [Cited by in F6Publishing: 72] [Article Influence: 6.1] [Reference Citation Analysis]
122 Sharma UR, Nediyedath Rathnakaran A, Raj BPP, Padinjakkara G, Das A, Vada S, Mudagal MP. The positive effect of pregnancy in rheumatoid arthritis and the use of medications for the management of rheumatoid arthritis during pregnancy. Inflammopharmacology 2021;29:987-1000. [PMID: 33844107 DOI: 10.1007/s10787-021-00808-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Corte C, Saxena P, Tattersall S, Selinger C, Leong RW. When to use biological agents in inflammatory bowel disease. J Gastroenterol Hepatol 2012;27:1141-9. [PMID: 22188169 DOI: 10.1111/j.1440-1746.2011.07056.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
124 Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:286-92; quiz e24. [PMID: 23200982 DOI: 10.1016/j.cgh.2012.11.011] [Cited by in Crossref: 298] [Cited by in F6Publishing: 250] [Article Influence: 33.1] [Reference Citation Analysis]
125 Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut. 2005;54:890. [PMID: 15888806 DOI: 10.1136/gut.2005.065417] [Cited by in Crossref: 111] [Cited by in F6Publishing: 81] [Article Influence: 6.9] [Reference Citation Analysis]
126 Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol. 2013;9:161-173; quiz 174. [PMID: 23390947 DOI: 10.1586/eci.12.103] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
127 Bae YC, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo B, Kimball AB. Review of treatment options for psoriasis in pregnant or lactating women: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology 2012;67:459-77. [DOI: 10.1016/j.jaad.2011.07.039] [Cited by in Crossref: 73] [Cited by in F6Publishing: 46] [Article Influence: 8.1] [Reference Citation Analysis]
128 Kane S. Trick or TREAT? More Safety Data of Infliximab During Pregnancy. Am J Gastroenterol 2018;113:1592-3. [PMID: 30333536 DOI: 10.1038/s41395-018-0372-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
129 Chambers CD, Johnson DL. Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy. Birth Defects Research Part A: Clinical and Molecular Teratology 2012;94:607-11. [DOI: 10.1002/bdra.23033] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
130 Tursi A. Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn’s disease. Dig Liver Dis. 2006;38:439-440. [PMID: 16563889 DOI: 10.1016/j.dld.2006.01.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
131 Narula N, Al-dabbagh R, Dhillon A, Sands BE, Marshall JK. Anti-TNFα Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflammatory Bowel Diseases 2014;20:1862-9. [DOI: 10.1097/mib.0000000000000092] [Cited by in Crossref: 51] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
132 Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Sarto P, Hansen TS, Wewer V, Bendtsen F. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6:1212-1217; quiz 1176. [PMID: 18848503 DOI: 10.1016/j.cgh.2008.05.010] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 7.5] [Reference Citation Analysis]
133 Abrouk M, Beroukhim K, Nakamura M, Zhu TH, Farahnik B, Singh R, Lee K, Koo J, Bhutani T. Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule. Int J Womens Dermatol 2017;3:S67-9. [PMID: 28492043 DOI: 10.1016/j.ijwd.2017.02.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
134 Ruiz V, Manubens E, Puig L. Psoriasis in pregnancy: a review (II). Actas Dermosifiliogr 2014;105:813-21. [PMID: 24314892 DOI: 10.1016/j.ad.2013.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
135 Fischer-Betz RE, Schneider M. [Biologics during pregnancy and breast--feeding]. Z Rheumatol 2010;69:780-7. [PMID: 21063826 DOI: 10.1007/s00393-010-0640-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
136 Kanis SL, de Lima-Karagiannis A, van der Ent C, Rizopoulos D, van der Woude CJ. Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type. J Crohns Colitis 2018;12:939-47. [PMID: 29771301 DOI: 10.1093/ecco-jcc/jjy058] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
137 Adar T, Grisaru-granovsky S, Ben Ya’acov A, Goldin E, Bar-gil Shitrit A. Pregnancy and the Immune System: General Overview and the Gastroenterological Perspective. Dig Dis Sci 2015;60:2581-9. [DOI: 10.1007/s10620-015-3683-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
138 Friedman S, McElrath TF, Wolf JL. Management of fertility and pregnancy in women with inflammatory bowel disease: a practical guide. Inflamm Bowel Dis. 2013;19:2937-2948. [PMID: 23945187 DOI: 10.1097/mib.0b013e3182a0ea6f] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
139 Kelly TF, Savides TJ. Gastrointestinal Disease in Pregnancy. Creasy and Resnik's Maternal-Fetal Medicine: Principles and Practice. Elsevier; 2009. pp. 1041-57. [DOI: 10.1016/b978-1-4160-4224-2.50052-1] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
140 Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn’s disease before and after delivery. J Clin Gastroenterol. 2009;43:613-616. [PMID: 19142167 DOI: 10.10.1097/mcg.0b013e31817f9367] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
141 Correia LM, Bonilha DQ, Ramos JD, Ambrogini O, Miszputen SJ. Treatment of inflammatory bowel disease and pregnancy: a review of the literature. Arq Gastroenterol 2010;47:197-201. [DOI: 10.1590/s0004-28032010000200016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
142 Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther. 2006;23:451-463. [PMID: 16441465 DOI: 10.1111/j.1365-2036.2006.02786.x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 162] [Article Influence: 11.2] [Reference Citation Analysis]
143 Van Assche G, Vermeire S, Rutgeerts P. Infliximab therapy for patients with inflammatory bowel disease: 10 years on. Eur J Pharmacol 2009;623 Suppl 1:S17-25. [PMID: 19837056 DOI: 10.1016/j.ejphar.2009.10.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
144 Korelitz BI. Continuing immunomodulators and biologic medications in pregnant IBD patients — Sometimes con: . Inflammatory Bowel Diseases 2007;13:1441-2. [DOI: 10.1002/ibd.20248] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
145 Osting VC, Carter JD. A safety assessment of tumor necrosis factor antagonists during pregnancy. Expert Opin Drug Saf. 2010;9:421-429. [PMID: 20367495 DOI: 10.1517/14740330903578639] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
146 Bortoli A, Saibeni S, Tatarella M, Prada A, Beretta L, Rivolta R, Politi P, Ravelli P, Imperiali G, Colombo E. Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case-control study. J Gastroenterol Hepatol. 2007;22:542-549. [PMID: 17376049 DOI: 10.1111/j.1440-1746.2006.04754.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 3.9] [Reference Citation Analysis]
147 Beaulieu DB, Kane S. Inflammatory bowel disease in pregnancy. World J Gastroenterol 2011; 17(22): 2696-2701 [PMID: 21734776 DOI: 10.3748/wjg.v17.i22.2696] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
148 Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol. 2009;36:635-641. [PMID: 19132789 DOI: 10.3899/jrheum.080545] [Cited by in Crossref: 195] [Cited by in F6Publishing: 144] [Article Influence: 16.3] [Reference Citation Analysis]
149 Youssef P, Kennedy D. Arthritis in pregnancy: the role and safety of biological agents. Obstet Med 2009;2:134-7. [PMID: 27579057 DOI: 10.1258/om.2009.090023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
150 Amate P, Seirafi M, Bouhnik Y, Luton D, Ducarme G. [Inflammatory bowel diseases: gynecological and obstetrical considerations]. J Gynecol Obstet Biol Reprod (Paris) 2011;40:612-9. [PMID: 21733636 DOI: 10.1016/j.jgyn.2011.05.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
151 Salmon JE, Alpert D. Are we coming to terms with tumor necrosis factor inhibition in pregnancy? Arthritis Rheum 2006;54:2353-5. [DOI: 10.1002/art.22027] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
152 Coburn LA, Wise PE, Schwartz DA. The Successful Use of Adalimumab to Treat Active Crohn's Disease of an Ileoanal Pouch During Pregnancy. Dig Dis Sci 2006;51:2045-7. [DOI: 10.1007/s10620-006-9452-2] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 4.7] [Reference Citation Analysis]
153 Blonski W, Lichtenstein GR. Safety of biologic therapy: . Inflammatory Bowel Diseases 2007;13:769-96. [DOI: 10.1002/ibd.20027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
154 Chaparro M, Gisbert JP. Successful use of infliximab for perianal Crohn’s disease in pregnancy. Inflamm Bowel Dis. 2011;17:868-869. [PMID: 20564533 DOI: 10.1002/ibd.21368] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
155 Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, Constantin A, Fautrel B, Gaudin P, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Huet I, Jullien D, Launay O, Lemann M, Maillefert JF, Marolleau JP, Martinez V, Masson C, Morel J, Mouthon L, Pol S, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Sudre A, Tran TA, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011;78 Suppl 1:15-185. [PMID: 21703545 DOI: 10.1016/S1297-319X(11)70001-X] [Cited by in Crossref: 53] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
156 Shihab Z, Yeomans ND, De Cruz P. Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis.J Crohns Colitis. 2016;10:979-988. [PMID: 26755733 DOI: 10.1093/ecco-jcc/jjv234] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
157 Perrone G, Brunelli R, Marcoccia E, Zannini I, Candelieri M, Gozzer M, Stefanutti C. Therapeutic Apheresis in Pregnancy: Three Differential Indications With Positive Maternal and Fetal Outcome: Therapeutic Apheresis in Pregnancy. Ther Apher Dial 2016;20:677-85. [DOI: 10.1111/1744-9987.12422] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol. 2014;43:78-84. [PMID: 24284028 DOI: 10.1016/j.reprotox.2013.11.004] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 8.3] [Reference Citation Analysis]
159 Gogia M, Furst DE. Rheumatoid arthritis and pregnancy: Disease activity, pregnancy outcomes, and treatment options during pregnancy and lactation. Drug Dev Res 2011;72:689-702. [DOI: 10.1002/ddr.20478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
160 Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, De Vitis I, Guidi L, Gasbarrini A. Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol. 2009;104:1575-1586. [PMID: 19491875 DOI: 10.1038/ajg.2009.162] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
161 Wan J, Imadojemu S, Werth VP. Management of rheumatic and autoimmune blistering disease in pregnancy and postpartum. Clinics in Dermatology 2016;34:344-52. [DOI: 10.1016/j.clindermatol.2016.02.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
162 Djokanovic N, Klieger-Grossmann C, Pupco A, Koren G. Safety of infliximab use during pregnancy. Reprod Toxicol. 2011;32:93-97. [PMID: 21621603 DOI: 10.1016/j.reprotox.2011.05.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
163 Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf. 2014;13:1699-1708. [PMID: 25406728 DOI: 10.1517/14740338.2014.973399] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
164 Calvo Alén J. Tratamiento de situaciones clínicas difíciles en pacientes con artritis reumatoide: Embarazo. Reumatología Clínica 2009;5:48-52. [DOI: 10.1016/j.reuma.2008.11.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
165 Florea A, Job-Deslandre C. [Rheumatoid arthritis and pregnancy]. Presse Med 2008;37:1644-51. [PMID: 18819772 DOI: 10.1016/j.lpm.2008.06.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
166 Casanova MJ, Chaparro M, Domènech E, Barreiro-de Acosta M, Bermejo F, Iglesias E, Gomollón F, Rodrigo L, Calvet X, Esteve M. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:433-440. [PMID: 23318480 DOI: 10.1038/ajg.2012.430] [Cited by in Crossref: 145] [Cited by in F6Publishing: 130] [Article Influence: 18.1] [Reference Citation Analysis]
167 D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007;56:725-32. [PMID: 17440187 DOI: 10.1136/gut.2006.103564] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 3.5] [Reference Citation Analysis]
168 Gisbert JP, Gomollón F. Errores frecuentes en el manejo del paciente ambulatorio con enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2007;30:469-86. [DOI: 10.1157/13110491] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
169 de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:985-1002. [PMID: 21936033 DOI: 10.1002/ibd.21871] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]